Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation
• Treatments: Idarubicin; Molgramostim

Criteria

Inclusion Criteria:

• Cytologic diagnosis of acute myeloblastic leukaemia (excluded M3)

• Over 65 years

Exclusion Criteria:

• Previous diagnosis of other malignancy hematopoietic disorder or myelodysplastic syndrome

• Previous treatment with antileucemic chemotherapy

• Psychiatric disorder

• Diagnosis of subtype FAB M3

• Creatinine > 2.5 mg/dL

• Bilirubin , Alkaline Phosphatase or transaminases three times upper the limit